Jade Biosciences (JBIO) Change in Accured Expenses (2020 - 2026)

Jade Biosciences has reported Change in Accured Expenses for 7 years, with the latest figure at $5.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 396.3% year-over-year to $5.8 million; the trailing twelve-month figure through Mar 2026 stood at $11.7 million (up 306.98% YoY), and the FY2025 full-year result was $3.9 million, up 2319.63% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $5.8 million, up from -$3.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $10.1 million in Q4 2023, with the low at -$3.5 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $1.5 million across 5 years, with a median of $497000.0 in 2022.
• The largest YoY upside for Change in Accured Expenses was 5257.14% in 2022 against a maximum downside of 6648.15% in 2022.
• Jade Biosciences' Change in Accured Expenses stood at -$1.8 million in 2022, then surged by 672.0% to $10.1 million in 2023, then sank by 60.64% to $4.0 million in 2024, then plunged by 187.84% to -$3.5 million in 2025, then surged by 265.1% to $5.8 million in 2026.
• The last three Change in Accured Expenses figures came in at $5.8 million (Q1 2026), -$3.5 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.